Vesilute peptide: the Khavinson bladder bioregulator, what is published and what is not

Vesilute is one of the least documented products in the Khavinson family. It is sold as a bladder bioregulator, a synthetic peptide meant to act on the tissue of the urinary bladder in the way the institute’s other short peptides are meant to act on their organs. The one peer-reviewed source that names it is a 2022 review from the institute on how short peptides might be transported into cells, which tabulates Vesilut (ED), the dipeptide glutamic acid–aspartic acid, with the activity bladder regulator and no supporting citation ^[1]. The same table lists a second bladder product, Kistiget (DG), also without a citation ^[1]. A 2023 follow-up paper includes ED among 26 peptides the institute regards as biologically active and among the peptides with the highest computed binding scores to the LAT1, LAT2 and PEPT1 transporters ^[2].

That is the whole of the primary literature. Supplier pages do not agree on what vesilute is: some give the sequence as Glu-Asp, matching the institute, while others give Lys-Glu-Asp, which is the published sequence of vesugen, the institute’s blood-vessel tripeptide ^{[5] [6]}. Buyers should be aware that a listing called vesilute may be describing one of two different molecules, and that the institute’s own account is the dipeptide.

Vesilute sits alongside the other short Khavinson peptides on this site: vesugen (Lys-Glu-Asp), chonluten (Glu-Asp-Gly), crystagen (Glu-Asp-Pro), ovagen (Glu-Asp-Leu) and pinealon (Glu-Asp-Arg). Each of those has at least one published experiment; vesilute, as far as we can find, has none.

The St Petersburg programme began in the 1970s with extracts of animal organs, the best known being thymalin from calf thymus and epithalamin from calf pineal gland. In 2002 Khavinson and Morozov reported that 266 elderly people given thymalin, epithalamin or both for the first two to three years of a six-to-eight-year follow-up had fewer acute respiratory infections, less ischaemic heart disease, hypertension and osteoporosis, and lower mortality than a control group, with a 4.1-fold fall in mortality in the group treated with both preparations every year ^[9]. That study is the foundation of the group’s claim that peptide bioregulators are geroprotectors. It was not blinded, the control group is not described in the abstract, and it has never been replicated outside the group.

The synthetic short peptides came later. Khavinson and Malinin set out the reasoning in a 2002 review: in their model, peptides normalise the synthesis of tissue-specific proteins and regulate the genes responsible for cell proliferation and differentiation, and in doing so maintain physiological function and slow ageing ^[8]. Under that model the institute produced a dipeptide or tripeptide for almost every organ, each named for its target and sold as a supplement: vesilute for the bladder, vesugen for blood vessels, pinealon for the brain, cartalax for cartilage and so on. These are the Khavinson peptides sold today. The synthetic peptides are called cytogens; the original extracts are called cytomaxes.

When reading claims about vesilute bioregulator products, three features of this literature matter. Almost every paper comes from one institute or its collaborators; many are in Russian in the institute’s own journal, Advances in Gerontology, with only an abstract in English; and the English-language papers are mostly in the Bulletin of Experimental Biology and Medicine, a translated Russian journal that is indexed in PubMed but does not amount to independent replication. For vesilute the problem is more basic: there is no paper at all, only a table entry.

The institute’s general hypothesis is that short peptides enter cells, bind particular DNA sequences in gene promoters and adjust the expression of tissue-specific genes ^[8]. No experiment has applied that hypothesis to vesilute or to the Glu-Asp dipeptide in bladder tissue. The only mechanistic material is computational: in the 2022 review, ED had the highest computed binding score to LAT1 of any peptide in the table ^[1], and the 2023 docking study again placed ED among the most effective computed ligands of the LAT and PEPT transporters ^[2]. Those are models of how a dipeptide might get into a cell, not evidence of what it does once there.

It is worth noting that Glu-Asp is not an exotic molecule. It is a fragment of countless proteins and is produced whenever they are digested, so any effect of a supplement would have to be distinguished from the body’s constant exposure to the same dipeptide from food. No study has attempted that.

Searches for vesilute benefits, and for vesilute bladder effects in particular, concern overactive bladder, incontinence, cystitis, prostate-related urinary symptoms and bladder ageing. We found no study of vesilute, Vesilut or the Glu-Asp dipeptide in any of those settings, in cells, in animals or in people. The claims on supplier pages describe restored bladder function and normalised bladder tissue in older people; none of them cites a paper, and we could not find one.

The institute has published on the bladder, but with different peptides. In 2001 Pliss and colleagues at the Petrov Institute of Oncology gave rats the bladder carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine and treated them with vilon, the Lys-Glu dipeptide. Bladder tumours developed in 56 per cent of vilon-treated rats against 75.5 per cent of controls, and preneoplastic changes in the bladder lining were halved ^[3]. A companion paper in Russian reported the same vilon result and found that epitalon, the Ala-Glu-Asp-Gly tetrapeptide, had no inhibitory effect ^[4]. Those studies are sometimes cited in support of vesilute; they do not involve it.

The Lys-Glu-Asp tripeptide that some sellers label as vesilute has its own published work as vesugen: it stimulated proliferation in skin explants from old rats ^[5] and increased the proliferative potential of immune cells in pineal gland culture without changing their differentiation ^[6]. Neither study concerned the bladder. If the product you are looking at is Lys-Glu-Asp, the vesugen guide describes what is known about it.

We found no clinical trial, case series or case report of vesilute or the Glu-Asp dipeptide in people in PubMed, and no registered study on ClinicalTrials.gov. The institute’s 2013 summary of the clinical results of its peptide preparations lists thymalin, thymogen, vilon, epithalamin, prostatilen, cortexin and retinalamin and does not mention a bladder peptide ^[7]. For a Khavinson peptide that has been given to people, see thymogen, which is a registered medicine in Russia; for a peptide with genuine urinary-tract animal data, see the vilon studies above ^{[3] [4]}.

There are no data. No study has given vesilute to an animal or a person and measured a bladder outcome over any period, so there is no published onset or duration of effect. Supplier statements about results after a course of capsules are not drawn from any study we could find.

None. There is no published dose of vesilute in any species. Suppliers sell it as 20 mg vials of lyophilised powder or as capsules and quote course lengths copied from the institute’s supplement marketing; those regimens have not been tested in any published study and are not recommendations. If you are working with the material in a laboratory, the vesilute calculator or the general peptide calculator converts vial contents to a concentration, and the molecular weight to use depends on which molecule the vial actually contains: about 262 g/mol for Glu-Asp and about 390 g/mol for Lys-Glu-Asp.

Research suppliers sell vesilute as a freeze-dried powder for reconstitution with bacteriostatic water and as oral capsules. No data exist on the absorption, distribution or fate of the product by any route. The institute’s modelling papers argue that di- and tripeptides could be absorbed through the PEPT1 transporter in the gut and enter cells through LAT carriers, and rank ED highly in those models ^{[1] [2]}; dietary Glu-Asp is in any case absorbed and broken down like any other dipeptide from protein digestion.

There is no published safety information on vesilute in animals or people. Glu-Asp itself is a normal product of protein digestion, which makes a toxic effect from small amounts unlikely but does not establish anything about a supplement marketed for the bladder. If the product is in fact Lys-Glu-Asp, the same absence of safety data applies to that tripeptide. People with urinary symptoms should note that no study has examined whether any of these peptides changes bladder function, and that persistent urinary symptoms have causes that a peptide would not address.

Vesilute is not named on the WADA Prohibited List or on the FDA’s lists of bulk substances for compounding as far as we have seen, which reflects the absence of any regulatory review. For rules on possession and sale, see our legal status overview.

Vesilute is not an approved medicine in any country we are aware of. In Russia the institute’s synthetic peptides are sold as dietary supplements rather than as registered drugs, in contrast to thymogen, which the same review describes as a medicinal product ^[1]. Outside Russia, products sold as vesilute are unlicensed research chemicals labelled for laboratory use.

See the UK, US and Europe pages for the rules that apply where you are, and our explainer on what research peptides are.

Vesilute is a small, water-soluble peptide supplied as a freeze-dried powder. It is generally stored refrigerated, dry and away from light, and reconstituted solutions are kept cold and used within a limited period. See how to store peptides.

The first question to ask a seller is which molecule the vial contains. A certificate of analysis should show a measured mass, and that mass answers it: about 262 g/mol means Glu-Asp, the sequence the institute gives; about 390 g/mol means Lys-Glu-Asp, which is vesugen under another name. A listing that gives one sequence and a COA that shows the other is a reason to walk away. Learn how to read a peptide COA and what third-party testing covers.

Compare vesilute prices across suppliers, including listings in the UK and US, and see our list of third-party tested suppliers. If a listing cites research on vesilute, ask for the reference; the bladder studies from the institute used vilon, not vesilute. Our guide to spotting a fake peptide supplier covers the other checks.